A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2131-2147

  Provenzano, Maurizio ^a   Sais, Giovanni ^a   Bracci, Laura ^a   Egli, Adrian ^b   Anselmi, Maurizio ^a   Viehl, Carsten T ^a   Schaub, Stefan ^a   Hirsch, Hans H ^b   Stroncek, David F ^c   Marincola, Francesco M ^c   Spagnoli, Giulio C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CLINICAL CENTER   (United States)

Author keywords

Immunotherapy; Peptide cross presentation; Vaccine

Indexed keywords

CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; HLA ANTIGEN; MATRIX PROTEIN; PHOSPHOPROTEIN; PRIMER DNA;

ALGORITHM; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHEMISTRY; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION;

ALGORITHMS; AMINO ACID SEQUENCE; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DNA PRIMERS; HLA ANTIGENS; HUMANS; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; POLYMERASE CHAIN REACTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 5;

EID: 72949083318     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00531.x     Document Type: Article

References (54)

1. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant. 2007 22 : viii72 82.
2. Gibson L, Dooley S, Trzmielina S, et al. Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants. J Infect Dis. 2007 195 : 1789 1798.
3. La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis. 2007 195 : 633 644.
4. Szmania S, Galloway A, Bruorton M, et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood. 2001 98 : 505 512.
5. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005 202 : 673 685.
6. Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum Immun. 2004 65 : 544 549.
7. Casazza JP, Betts MR, Price DA, et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med. 2006 203 : 2865 2877.
8. Zhou W, Sharma M, Martinez J, et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol. 2007 20 : 379 388.
9. Zaunders JJ, Dyer WB, Wang B, et al. Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood. 2004 103 : 2238 2247.
10. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002 99 : 3916 3922.
11. Gamadia LE, Remmerswaal EB, Weel JF, et al. Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood. 2003 101 : 2686 2692.
12. Kobayashi H, Nagato T, Takahara M, et al. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res. 2008 68 : 901 908.
13. Burrows JM, Wynn KK, Tynan FE, et al. The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur J Immunol. 2007 37 : 946 953.
14. Slezak SL, Bettinotti M, Selleri S, et al. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007 5 : 17.
15. Provenzano M, Selleri S, Jin P, et al. Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. Cancer Immunol Immunother. 2007 56 : 1047 1063.
16. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004 4 : 725 738.
17. Lim JB, Provenzano M, Kwon OH, et al. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. Exp Hematol. 2006 34 : 296 307.
18. Ghei M, Stroncek DF, Provenzano M. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J Transl Med. 2005 3 : 23.
19. Gault E, Michel Y, Dehee A, et al. Quantification of human cytomegalovirus DNA by real-time PCR. J Clin Microbiol. 2001 39 : 772 775.
20. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008 6 : 29.
21. Gerna G, Percivalle E, Lilleri D, et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol. 2005 86 : 275 284.
22. Provenzano M, Mocellin S, Bettinotti M, et al. Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother. 2002 25 : 342 351.
23. Mocellin S, Provenzano M, Rossi CR, et al. Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J Immunol Methods. 2003 280 : 1 11.
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods San Diego, Calif. 2001 25 : 402 408.
25. Liu L, Chahroudi A, Silvestri G, et al. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med. 2002 8 : 185 189.
26. Provenzano M, Bracci L, Wyler S, et al. Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med. 2006 4 : 47.
27. Shimonkevitz R, Kappler J, Marrack P, et al. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med. 1983 158 : 303 316.
28. Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood. 1997 90 : 1751 1767.
29. Bednarek MA, Sauma SY, Gammon MC, et al. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol. 1991 147 : 4047 4053.
30. Nastke MD, Herrgen L, Walter S, et al. Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci. 2005 62 : 77 86.
31. Kuzushima K, Hayashi N, Kimura H, et al. Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood. 2001 98 : 1872 1881.
32. Mora JR, Cheng G, Picarella D, et al. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med. 2005 201 : 303 316.
33. Lozza L, Lilleri D, Percivalle E, et al. Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol. 2005 35 : 1795 1804.
34. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood. 1999 93 : 394 398.
35. Schleiss M. Progress in cytomegalovirus vaccine development. Herpes. 2005 12 : 66 75.
36. Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med. 2006 12 : 26 33.
37. Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology. 2001 104 : 367 376.
38. Provenzano M, Panelli MC, Mocellin S, et al. MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol Med. 2006 12 : 465 472.
39. Anderton SM, Radu CG, Lowrey PA, et al. Negative selection during the peripheral immune response to antigen. J Exp Med. 2001 193 : 1 11.
40. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994 152 : 163 175.
41. Rammensee H, Bachmann J, Emmerich NP, et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999 50 : 213 219.
42. Harcourt GC, Scriba TJ, Semmo N, et al. Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol. 2006 146 : 203 210.
43. Trivedi D, Williams RY, O'Reilly RJ, et al. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005 105 : 2793 2801.
44. Bronke C, Palmer NM, Westerlaken GH, et al. Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immun. 2005 66 : 950 961.
45. Kondo E, Akatsuka Y, Kuzushima K, et al. Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood. 2004 103 : 630 638.
46. Langenkamp A, Messi M, Lanzavecchia A, et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol. 2000 1 : 311 316.
47. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, et al. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood. 2006 108 : 3121 3127.
48. Mertz AK, Wu P, Sturniolo T, et al. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J Immunol. 2000 164 : 1529 1537.
49. Neumann F, Wagner C, Kubuschok B, et al. Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 2004 53 : 589 599.
50. Panina-Bordignon P, Tan A, Termijtelen A, et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol. 1989 19 : 2237 2242.
51. Zarour HM, Maillere B, Brusic V, et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002 62 : 213 218.
52. Adamina M, Weber WP, Rosenthal R, et al. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials. 2008 29 : 165 181.
53. Schumacher R, Amacker M, Neuhaus D, et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine. 2005 23 : 5572 5582.
54. Zajac P, Oertli D, Marti W, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther. 2003 14 : 1497 1510.